PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-24
DOI
10.1007/s00259-020-05040-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer
- (2020) Robert Seifert et al. JOURNAL OF NUCLEAR MEDICINE
- qPSMA: a semi-automatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET/CT
- (2019) Andrei Gafita et al. JOURNAL OF NUCLEAR MEDICINE
- TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer.
- (2019) Michael Hofman et al. JOURNAL OF CLINICAL ONCOLOGY
- EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
- (2019) Clemens Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Is the “VISION” of Radioligand Therapy for Prostate Cancer becoming reality? An Overview of the Phase III trial and the Importance for the Future of Theranostics
- (2019) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
- (2019) Michael S. Hofman et al. BJU INTERNATIONAL
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
- (2018) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
- (2018) Christos E. Kyriakopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic Prostate Cancer
- (2018) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer
- (2018) Andrew J. Armstrong et al. JAMA Oncology
- Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and “whole body” tumor dosimetry with treatment outcomes
- (2018) John A Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Neuroendocrine differentiation of prostate cancer leads to PSMA suppression
- (2018) Martin K Bakht et al. ENDOCRINE-RELATED CANCER
- 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour
- (2017) Christian Uprimny et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
- (2016) Kambiz Rahbar et al. CLINICAL NUCLEAR MEDICINE
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
- (2016) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now